裴安德表示，每次来到中国上海，都惊叹于中国、上海的发展活力和创新速度。中国发展规划的连续性 战略性和上海务实高效的营商环境，坚定了企业投资深耕的信心决心。将以蔡司大中华区总部综合园区 在沪启动建设为契机，携手合作伙伴推动技术创新、产业创新，提供更专业更高品质的产品服务和解决 方案，更好推动可持续发展。 市领导李政、华源参加相关会见。 本报讯 市委书记陈吉宁近日分别会见了勃林格殷格翰股东委员会主席冯保和、蔡司集团总裁兼首席执 行官裴安德。 陈吉宁介绍了上海"十五五"规划相关情况。他说，今年是中国"十五五"开局之年，上海正按照习近平主 席重要指示要求，更加积极主动扩大高水平对外开放，把科技创新摆在更加突出位置，深化"五个中 心"建设，推动高质量发展。我们制定实施"十五五"规划，确定上海未来五年发展目标任务，以发展环 境的长期、稳定、透明和可预期，为全球企业在沪深耕发展提供新的机遇，拓展更为广阔的合作空间。 生物医药是上海重点发展的三大先导产业之一，勃林格殷格翰是全球领先的生物制药企业，欢迎持续加 大在沪创新研发和业务布局力度，围绕基础研究、临床试验、生产制造等加强新药开发合作，参与构建 开放创新生态。用好东方枢纽 ...

Group 1 - Shanghai is actively expanding high-level opening-up and placing greater emphasis on technological innovation as part of its "14th Five-Year Plan" [2] - The biopharmaceutical industry is one of the three key leading industries in Shanghai, with Boehringer Ingelheim being a global leader in biopharmaceuticals [2] - Shanghai aims to create a long-term, stable, transparent, and predictable development environment to provide new opportunities for global enterprises [2] Group 2 - Boehringer Ingelheim is committed to increasing its innovation investment in Shanghai and collaborating with partners to deepen innovation and research and development [3] - Carl Zeiss AG is focused on leveraging its brand, professional, and innovation advantages to enhance its regional headquarters' functions in Shanghai [3] - Both companies are encouraged to participate in building a more competitive industrial ecosystem and to achieve breakthrough innovations in global markets [3]

（文章来源：第一财经） 据上海发布，上海市委书记陈吉宁近日分别会见了勃林格殷格翰股东委员会主席冯保和、蔡司集团总裁 兼首席执行官裴安德。 陈吉宁介绍了上海"十五五"规划相关情况。他说，生物医药是上海重点发展的三大先导产业之一，勃林 格殷格翰是全球领先的生物制药企业，欢迎持续加大在沪创新研发和业务布局力度，围绕基础研究、临 床试验、生产制造等加强新药开发合作，参与构建开放创新生态。用好东方枢纽国际商务合作区功能优 势，不断拓展新业务、新场景、新服务。蔡司是全球领先的光学和光电设备制造商，核心业务、战略愿 景与上海产业发展定位相契合，欢迎更好发挥企业品牌优势、专业优势、创新优势，进一步提升地区总 部功能作用，加大在沪研发制造布局，积极参与构建更具竞争力的产业生态，在面向全球市场、深化开 放合作中取得更多突破性创新性成果。上海将持续营造市场化、法治化、国际化一流营商环境，在常态 化听取企业意见建议中不断优化政策制度供给，提供便利高效服务，及时解决具体问题，支持各类企业 在沪取得更好发展。 ...

Group 1 - Shanghai is focusing on creating a long-term, stable, transparent, and predictable development environment to provide new opportunities for global enterprises [2] - The "14th Five-Year Plan" emphasizes high-level opening up and prioritizes technological innovation, aiming for high-quality development in Shanghai [2] - The biopharmaceutical industry is one of the three key leading industries in Shanghai, with a call for increased innovation and collaboration in drug development from global leaders like Boehringer Ingelheim [2] Group 2 - Zeiss, a leading manufacturer of optical and optoelectronic equipment, is encouraged to enhance its regional headquarters functions and increase R&D and manufacturing presence in Shanghai [2] - Both companies expressed commitment to deepening innovation and collaboration in the Chinese market, with Boehringer Ingelheim focusing on human pharmaceuticals and animal health [4] - Zeiss highlighted the importance of Shanghai's business environment and strategic development plans, reinforcing its investment confidence in the region [4]